Most cardiovascular risk goes undetected until it becomes clinical — and one underappreciated reason is that conventional fasting glucose tests miss the turbulent glycemic swings that occur between meals. A narrative review published in Medicina proposes that continuous glucose monitoring, long confined to diabetes management, could become a frontline precision tool for cardiovascular prevention in metabolically healthy adults — a conceptual shift with meaningful implications for longevity medicine.
The review synthesizes evidence from prospective cohorts, randomized controlled trials, and mechanistic studies to argue that CGM-derived glycemic variability metrics — invisible to standard HbA1c or fasting glucose assessments — capture endothelial injury and inflammatory signaling triggered by postprandial glucose excursions, even within the technically "normal" glycemic range. The authors examine how CGM feedback can enable dietary personalization, and separately evaluate the cardiovascular and longevity profiles of low-dose metformin and acarbose as pharmacological adjuncts targeting nutrient-sensing pathways such as AMPK and mTOR. The central hypothesis is that CGM-guided metabolic phenotyping, combined with structured fasting protocols and selective longevity-oriented pharmacotherapy, constitutes a mechanistically coherent preventive strategy capable of attenuating both cardiovascular risk and biological aging in non-diabetic individuals.
This is a hypothesis-generating narrative review, not an intervention trial — a distinction that matters enormously. Narrative reviews are inherently selective in evidence, and no prospective outcome data yet demonstrate that CGM-guided interventions in non-diabetics actually reduce cardiovascular events or extend healthspan. That said, the underlying mechanistic biology is credible: glycemic variability's role in vascular inflammation is well-supported at the cellular level, and CGM costs are declining sharply, making population-level applicability more realistic. The review sits at the convergence of precision cardiology, longevity pharmacology, and wearable biosensing — an intersection that is growing rapidly. Its primary value is framing a testable clinical hypothesis; confirmation will require large randomized trials with hard endpoints. As an intellectual roadmap, it is timely and well-constructed.
